Skip to main content

and
  1. Article

    Open Access

    Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI

    To enhance the success rate of antiangiogenic therapies in the clinic, it is crucial to identify parameters for tumour angiogenesis that can predict response to these therapies. In brain tumours, one such para...

    G Gambarota, W Leenders, C Maass, P Wesseling, B van der Kogel in British Journal of Cancer (2008)

  2. Article

    Open Access

    P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo

    ABC transporter proteins may protect haematopoietic progenitor cells from chemotherapy-induced toxicity. By using an in vitro colony-forming assay, we found that bone marrow of Mdr1ab, Mrp1, Mdr1ab/Mrp1 knockout ...

    O van Tellingen, T Buckle, J W Jonker, M A van der Valk in British Journal of Cancer (2003)

  3. No Access

    Article

    A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

    Abstract

    H. van den Bongard, R. Mathôt, O. van Tellingen in Cancer Chemotherapy and Pharmacology (2002)

  4. Article

    Open Access

    The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

    The purpose of this study was to investigate the effect of the co-solvents Cremophor EL and polysorbate 80 on the absorption of orally administered paclitaxel. 6 patients received in a randomized setting, one ...

    M M Malingré, J H M Schellens, O Van Tellingen, M Ouwehand in British Journal of Cancer (2001)

  5. Article

    Open Access

    Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

    The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might offer equivalent antitumour efficacy and reduced haematological toxicity, without...

    F Doz, J C Gentet, F Pein, D Frappaz, P Chastagner, S Moretti in British Journal of Cancer (2001)

  6. Article

    Open Access

    Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

    The non-linear plasma pharmacokinetics of paclitaxel in patients has been well established, however, the exact underlying mechanism remains to be elucidated. We have previously shown that the non-linear plasma...

    O van Tellingen, M T Huizing, V R Nannan Panday in British Journal of Cancer (1999)

  7. Article

    Open Access

    Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

    Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanc...

    A Awada, C J A Punt, M J Piccart, O Van Tellingen, L Van Manen in British Journal of Cancer (1999)

  8. Article

    Open Access

    Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

    To gain more insight into the pharmacological role of endogenous P-glycoprotein in the metabolism of the widely used substrate drug doxorubicin, we have studied the plasma pharmacokinetics, tissue distribution...

    J van Asperen, O van Tellingen, F Tijssen, A H Schinkel in British Journal of Cancer (1999)

  9. No Access

    Article

    A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

    We investigated the pharmacokinetic behavior of carzelesin in 31 patients receiving this drug by 10-min intravenous infusion in a Phase I clinical trial, which was conducted at institutions in Nijmegen (insti...

    O. van Tellingen, C. J. A. Punt, A. Awada in Cancer Chemotherapy and Pharmacology (1998)

  10. No Access

    Article

    Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

    Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated w...

    J van Asperen, O van Tellingen, A Sparreboom, AH Schinkel in British Journal of Cancer (1997)

  11. No Access

    Article

    Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion

     We investigated the pharmacokinetics of etoposide given to a patient suffering from multifocal liver metastases from an unknown primary tumor. The drug was given either by i.v. infusion or by hepatic arterial...

    O. van Tellingen, Maarten T. Kuck, L. T. Vlasveld in Cancer Chemotherapy and Pharmacology (1996)

  12. No Access

    Article

    Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets

    We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving moderatel...

    R de Wit, JH Beijnen, O van Tellingen, JHM Schellens in British Journal of Cancer (1996)

  13. No Access

    Article

    Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides

    Cytotoxic effects ofcis-diamminedichloroplatinum-(II) (cis-DDP) are thought to be mediated by binding to DNA. Studies on binding ofcis-DDP to cellular DNA rely heavily on the availability of specific antibodies. ...

    P. M. A. B. Terheggen, B. G. J. Floot in Cancer Chemotherapy and Pharmacology (1991)